Codexis to produce synthetic RNA for innovative therapeutic applications.
- Codexis to produce 50 g of synthetic RNA.
- Manufacturing utilizes an eco-friendly synthesis platform.
- Agreement supports innovative therapeutic products.
Codexis has announced a new agreement focused on siRNA manufacturing, set to produce 50 grams of synthetic RNA. This production will utilize the company's eco-synthesis manufacturing platform, which aims to streamline the process while minimizing environmental impact. The partnership highlights Codexis's commitment to advancing therapeutic applications through innovative biotechnological methods.
The eco-synthesis platform employed by Codexis allows for efficient and environmentally sustainable production of siRNA. This advancement is expected to support a range of therapeutic products, enabling further research and development in RNA-based treatments. The agreement emphasizes a significant step in enhancing accessibility to critical biological materials needed for modern therapeutics.
As synthetic RNA plays an important role in developing targeted therapies, the agreement marks a noteworthy development in the biopharmaceutical industry. Codexis's expertise in this area will potentially accelerate progress in RNA therapeutics, offering new avenues for treatment and research. The focus on sustainability within the manufacturing process underscores the industry's shift towards greener practices.
